OCTOBER 01, 2019
Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer
SEPTEMBER 23, 2019
Dyne Therapeutics Announces Support for ReSolve Natural History Study of Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)
